These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25401718)

  • 1. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.
    Vázquez-Bourgon J; Rodríguez-Rodríguez P; Gómez-Ruíz E; Artal J; Crespo-Facorro B
    Ann Clin Psychiatry; 2014 Nov; 26(4):301-2. PubMed ID: 25401718
    [No Abstract]   [Full Text] [Related]  

  • 2. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.
    Jones A
    J Psychiatr Ment Health Nurs; 2008 Dec; 15(10):792-9. PubMed ID: 19012670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone for treatment of schizophrenia.
    Nussbaum AM; Stroup TS
    Schizophr Bull; 2008 May; 34(3):419-22. PubMed ID: 18375569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible neuroleptic malignant syndrome during paliperidone administration: a case report.
    Mantas C; Kalabokis G; Goulia P; Tourlakopoulos A; Hyphantis T; Mavreas V
    J Clin Psychopharmacol; 2010 Feb; 30(1):89-91. PubMed ID: 20075663
    [No Abstract]   [Full Text] [Related]  

  • 5. Paliperidone overdose in a patient with schizophrenia.
    Chang JP; Huang CC; Su KP
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):418. PubMed ID: 19995588
    [No Abstract]   [Full Text] [Related]  

  • 6. Paliperidone extended release.
    Yang LP; Plosker GL
    CNS Drugs; 2007; 21(5):417-25; discussion 426-7. PubMed ID: 17447829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
    Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR
    J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecule of the month. Paliperidone.
    Drug News Perspect; 2007 Jun; 20(5):333. PubMed ID: 17878961
    [No Abstract]   [Full Text] [Related]  

  • 9. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
    Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
    Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
    J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone-associated motor tics.
    Hsieh MH; Chiu NY
    Gen Hosp Psychiatry; 2014; 36(3):360.e7-8. PubMed ID: 24556260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report.
    Angelucci F; Ricci V; Martinotti G; Caltagirone C; Bria P
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1277-8. PubMed ID: 19555731
    [No Abstract]   [Full Text] [Related]  

  • 15. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
    Cleton A; Rossenu S; Crauwels H; Berwaerts J; Hough D; Gopal S; Eerdekens M; Vandebosch A; Remmerie B; De Meulder M; Rosso CM
    J Clin Pharmacol; 2014 Sep; 54(9):1048-57. PubMed ID: 24676998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In brief: Injectable paliperidone palmitate for schizophrenia.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):88. PubMed ID: 19890247
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.
    Han C; Lee SJ; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):650-1. PubMed ID: 21163319
    [No Abstract]   [Full Text] [Related]  

  • 19. Paliperidone: An improvement over risperidone?
    Dopheide JA
    Am J Health Syst Pharm; 2008 Mar; 65(5):401. PubMed ID: 18281730
    [No Abstract]   [Full Text] [Related]  

  • 20. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
    J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.